Search
Tifurac
go.drugbank.com/drugs/DB21415ExperimentalTifurac is a small molecule drug. The usage of the INN stem '-ac' in the name indicates that Tifurac is a anti-inflammatory agent, ibufenac derivative. … Tifurac has a monoisotopic molecular weight of 326.06 Da.
beta-Hydroxybutyric acid
go.drugbank.com/drugs/DB16506InvestigationalBeta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236 (completed for type 1 dia...
Tezacitabine
go.drugbank.com/drugs/DB06433InvestigationalA synthetic purine nucleoside analogue with potential antineoplastic activity.
CR002
go.drugbank.com/drugs/DB05139InvestigationalCR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. … This is a novel therapeutic approach to treat kidney inflammation.
PRO-542
go.drugbank.com/drugs/DB05793InvestigationalPRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. … PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates.
Gallium maltolate
go.drugbank.com/drugs/DB05420InvestigationalGallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.
Aniline
go.drugbank.com/drugs/DB06728InvestigationalAniline, phenylamine or aminobenzene is an organic compound with the formula C6H5NH2. Consisting of an amine attached to a benzene ring, aniline is the prototypical aromatic amine. … Aniline is colorless, but it slowly oxidizes and resinifies in air, giving a red-brown tint to aged samples.
Nirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigationalNirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. … granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase 3 DeFi trial, where a
AAV-AIPL
go.drugbank.com/drugs/DB17857ExperimentalAAV-AIPL is an adenovirus-associated viral vector serotype 8 containing the human _AIPL1_ gene.